Sulindac derivatives that activate the peroxisome proliferator-activated receptor γ but lack cyclooxygenase inhibition

Andrew S. Felts, Brianna S. Siegel, Shiu M. Young, Christopher W. Moth, Terry P. Lybrand, Andrew J. Dannenberg, Lawrence J. Marnett, Kotha Subbaramaiah

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A series of novel derivatives of the nonsteroidal anti-inflammatory drug (NSAID) sulindac sulfide were synthesized as potential agonists of the peroxisome proliferator-activated receptor gamma (PPARγ). Nonpolar and aromatic substitutions on the benzylidene ring as well as retention of the carboxylic acid side chain were required for optimal activity. Compound 24 was as potent a compound as any other in the series with an EC50 of 0.1 μM for the induction of peroxisome proliferator response element (PPRE)-luciferase activity. Direct binding of compound 24 to PPARγ was demonstrated by the displacement of [3H]troglitazone, a PPARγ agonist, in a scintillation proximity assay. Compound 24 also stimulated the binding of PPARγ to a PPRE-containing oligonucleotide and induced expression of liver fatty-acid binding protein (L-FABP) and adipocyte fatty acid-binding protein (aP2), two established PPARγ target genes. Taken together, these compounds represent potential leads in the development of novel PPARγ agonists.

Original languageEnglish (US)
Pages (from-to)4911-4919
Number of pages9
JournalJournal of Medicinal Chemistry
Volume51
Issue number16
DOIs
StatePublished - Aug 28 2008
Externally publishedYes

Fingerprint

Sulindac
Peroxisome Proliferator-Activated Receptors
PPAR gamma
Prostaglandin-Endoperoxide Synthases
Derivatives
Peroxisome Proliferators
Fatty Acid-Binding Proteins
troglitazone
Response Elements
Scintillation
Carboxylic Acids
Luciferases
Adipocytes
Oligonucleotides
Assays
Substitution reactions
Anti-Inflammatory Agents
Genes
Pharmaceutical Preparations
N-dodecyl-L-lysine amide

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Sulindac derivatives that activate the peroxisome proliferator-activated receptor γ but lack cyclooxygenase inhibition. / Felts, Andrew S.; Siegel, Brianna S.; Young, Shiu M.; Moth, Christopher W.; Lybrand, Terry P.; Dannenberg, Andrew J.; Marnett, Lawrence J.; Subbaramaiah, Kotha.

In: Journal of Medicinal Chemistry, Vol. 51, No. 16, 28.08.2008, p. 4911-4919.

Research output: Contribution to journalArticle

Felts, AS, Siegel, BS, Young, SM, Moth, CW, Lybrand, TP, Dannenberg, AJ, Marnett, LJ & Subbaramaiah, K 2008, 'Sulindac derivatives that activate the peroxisome proliferator-activated receptor γ but lack cyclooxygenase inhibition', Journal of Medicinal Chemistry, vol. 51, no. 16, pp. 4911-4919. https://doi.org/10.1021/jm700969c
Felts, Andrew S. ; Siegel, Brianna S. ; Young, Shiu M. ; Moth, Christopher W. ; Lybrand, Terry P. ; Dannenberg, Andrew J. ; Marnett, Lawrence J. ; Subbaramaiah, Kotha. / Sulindac derivatives that activate the peroxisome proliferator-activated receptor γ but lack cyclooxygenase inhibition. In: Journal of Medicinal Chemistry. 2008 ; Vol. 51, No. 16. pp. 4911-4919.
@article{23cb120abecf4e358397cf1620442b45,
title = "Sulindac derivatives that activate the peroxisome proliferator-activated receptor γ but lack cyclooxygenase inhibition",
abstract = "A series of novel derivatives of the nonsteroidal anti-inflammatory drug (NSAID) sulindac sulfide were synthesized as potential agonists of the peroxisome proliferator-activated receptor gamma (PPARγ). Nonpolar and aromatic substitutions on the benzylidene ring as well as retention of the carboxylic acid side chain were required for optimal activity. Compound 24 was as potent a compound as any other in the series with an EC50 of 0.1 μM for the induction of peroxisome proliferator response element (PPRE)-luciferase activity. Direct binding of compound 24 to PPARγ was demonstrated by the displacement of [3H]troglitazone, a PPARγ agonist, in a scintillation proximity assay. Compound 24 also stimulated the binding of PPARγ to a PPRE-containing oligonucleotide and induced expression of liver fatty-acid binding protein (L-FABP) and adipocyte fatty acid-binding protein (aP2), two established PPARγ target genes. Taken together, these compounds represent potential leads in the development of novel PPARγ agonists.",
author = "Felts, {Andrew S.} and Siegel, {Brianna S.} and Young, {Shiu M.} and Moth, {Christopher W.} and Lybrand, {Terry P.} and Dannenberg, {Andrew J.} and Marnett, {Lawrence J.} and Kotha Subbaramaiah",
year = "2008",
month = "8",
day = "28",
doi = "10.1021/jm700969c",
language = "English (US)",
volume = "51",
pages = "4911--4919",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Sulindac derivatives that activate the peroxisome proliferator-activated receptor γ but lack cyclooxygenase inhibition

AU - Felts, Andrew S.

AU - Siegel, Brianna S.

AU - Young, Shiu M.

AU - Moth, Christopher W.

AU - Lybrand, Terry P.

AU - Dannenberg, Andrew J.

AU - Marnett, Lawrence J.

AU - Subbaramaiah, Kotha

PY - 2008/8/28

Y1 - 2008/8/28

N2 - A series of novel derivatives of the nonsteroidal anti-inflammatory drug (NSAID) sulindac sulfide were synthesized as potential agonists of the peroxisome proliferator-activated receptor gamma (PPARγ). Nonpolar and aromatic substitutions on the benzylidene ring as well as retention of the carboxylic acid side chain were required for optimal activity. Compound 24 was as potent a compound as any other in the series with an EC50 of 0.1 μM for the induction of peroxisome proliferator response element (PPRE)-luciferase activity. Direct binding of compound 24 to PPARγ was demonstrated by the displacement of [3H]troglitazone, a PPARγ agonist, in a scintillation proximity assay. Compound 24 also stimulated the binding of PPARγ to a PPRE-containing oligonucleotide and induced expression of liver fatty-acid binding protein (L-FABP) and adipocyte fatty acid-binding protein (aP2), two established PPARγ target genes. Taken together, these compounds represent potential leads in the development of novel PPARγ agonists.

AB - A series of novel derivatives of the nonsteroidal anti-inflammatory drug (NSAID) sulindac sulfide were synthesized as potential agonists of the peroxisome proliferator-activated receptor gamma (PPARγ). Nonpolar and aromatic substitutions on the benzylidene ring as well as retention of the carboxylic acid side chain were required for optimal activity. Compound 24 was as potent a compound as any other in the series with an EC50 of 0.1 μM for the induction of peroxisome proliferator response element (PPRE)-luciferase activity. Direct binding of compound 24 to PPARγ was demonstrated by the displacement of [3H]troglitazone, a PPARγ agonist, in a scintillation proximity assay. Compound 24 also stimulated the binding of PPARγ to a PPRE-containing oligonucleotide and induced expression of liver fatty-acid binding protein (L-FABP) and adipocyte fatty acid-binding protein (aP2), two established PPARγ target genes. Taken together, these compounds represent potential leads in the development of novel PPARγ agonists.

UR - http://www.scopus.com/inward/record.url?scp=50249111494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249111494&partnerID=8YFLogxK

U2 - 10.1021/jm700969c

DO - 10.1021/jm700969c

M3 - Article

C2 - 18665581

AN - SCOPUS:50249111494

VL - 51

SP - 4911

EP - 4919

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -